Jon Snodgres Biography and Net Worth

CFO of Repligen

Jon K. Snodgres joined Repligen in July 2014 as the Chief Financial Officer, where he oversees financial operations for the Company. Mr. Snodgres was previously with Maquet Cardiovascular (“Maquet”), a medical device company, where he served as Chief Financial Officer for five years. At Maquet, in addition to being responsible for the preparation and oversight of the company’s financial statements, he was a key participant in growth planning and profit improvement strategies. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific in various roles, most recently as Vice President of Finance for the Laboratory Products Group. He began his career in finance at AlliedSignal/Honeywell International. Mr. Snodgres received a B.S. in Business Administration, Finance from Northern Arizona University.

What is Jon Snodgres' net worth?: The estimated net worth of Jon Snodgres is at least $4.90 million as of August 16th, 2022. Mr. Snodgres owns 34,506 shares of Repligen stock worth more than $4,898,127 as of March 26th. This net worth evaluation does not reflect any other assets that Mr. Snodgres may own. Learn More about Jon Snodgres' net worth.
How do I contact Jon Snodgres?: The corporate mailing address for Mr. Snodgres and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at investors@repligen.com. Learn More on Jon Snodgres' contact information.
Has Jon Snodgres been buying or selling shares of Repligen?: Jon Snodgres has not been actively trading shares of Repligen during the past quarter. Most recently, Jon Snodgres sold 6,698 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $252.86, for a transaction totalling $1,693,656.28. Following the completion of the sale, the chief financial officer now directly owns 34,506 shares of the company's stock, valued at $8,725,187.16. Learn More on Jon Snodgres' trading history.
Who are Repligen's active insiders?: Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (Executive Chair), Ralf Kuriyel (VP), Martin Madaus (Director), Margaret Pax (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?: In the last year, Repligen insiders bought shares 3 times. They purchased a total of 3,865 shares worth more than $487,610.60. In the last year, insiders at the biotechnology company sold shares 3 times. They sold a total of 46,728 shares worth more than $7,342,936.94. The most recent insider tranaction occured on March, 17th when Director Margaret Pax bought 250 shares worth more than $37,672.50. Insiders at Repligen own 1.2% of the company. Learn More about insider trades at Repligen.
Information on this page was last updated on 3/17/2025.

Jon Snodgres Insider Trading History at Repligen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2022	Sell	6,698	$252.86	$1,693,656.28	34,506
8/1/2022	Sell	2,000	$220.00	$440,000.00	37,187
5/14/2021	Sell	470	$172.60	$81,122.00	31,893
3/4/2021	Sell	3,545	$192.47	$682,306.15	35,708
1/4/2021	Sell	3,957	$191.52	$757,844.64	32,799
11/9/2020	Sell	705	$194.69	$137,256.45	31,562
5/15/2020	Sell	660	$140.43	$92,683.80	32,267
5/13/2020	Sell	15,394	$128.74	$1,981,823.56	39,297
3/3/2020	Sell	610	$88.18	$53,789.80	37,172
2/26/2020	Sell	1,100	$86.22	$94,842.00	32,042
3/25/2019	Sell	6,467	$58.54	$378,578.18	21,543
3/5/2019	Sell	2,645	$58.52	$154,785.40	29,646
2/28/2019	Sell	1,875	$58.88	$110,400.00	26,821
11/26/2018	Sell	31,753	$63.49	$2,015,997.97	32,344
8/28/2018	Sell	14,460	$52.79	$763,343.40	20,899
3/17/2017	Sell	1,909	$34.91	$66,643.19	23,789

Jon Snodgres Buying and Selling Activity at Repligen

Repligen Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $141.95

$140.20

$147.00

50 Day Range

MA: $155.62

$136.99

$174.24

2 Week Range

Now: $141.95

$113.50

$187.25

Volume

730,947 shs

Average Volume

652,284 shs

Market Capitalization

$7.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95